Latest Pharma and Biotech News
Biotechnology
19 December 2024 Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx.
Today's issue
Refine Search
Pharmaceutical
San Diego, USA-based Neurocrine Biosciences today announced the launch of its Crenessity (crinecerfont) in the USA. 20 December 2024
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Biotechnology
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula (niraparib) and Jemperli (dostarlimab) in first line advanced ovarian cancer. 20 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting distinct domains of Factor XI, supporting its bid to bring new blood thinners to the market. 20 December 2024
Pharmaceutical
Denmark’s Zealand Pharma has been hit with a complete response letter (CRL) from the US regulator for glepaglutide, a long-acting GLP-2 analog. 20 December 2024
Biotechnology
Astellas Pharma has struck a licensing agreement with Sangamo Therapeutics to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. 20 December 2024
Biotechnology
Swiss pharma giant Novartis is to shut two sites belonging to its MorphoSys unit. 20 December 2024
Pharmaceutical
Denmark’s Novo Nordisk today announced headline results from REDEFINE 1, a Phase III trial in the global REDEFINE program, which it said were positive, but failed to impress investors, who pushed the firms shares down 19% to 601.30 kroner. 20 December 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). 20 December 2024
Pharmaceutical
US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL). 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) today recommending Pedmarqsi (anhydrous sodium thiosulfate), from British specialty pharma firm Norgine Pharmaceuticals, for the prevention of cisplatin-induced ototoxicity (CIO) in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors. 20 December 2024
Pharmaceutical
Shanghai-based Fangzhou, has entered into a strategic partnership with the Chinese business of Bristol Myers Squibb China, with the goal of enhancing digital platforms for chronic disease management. 19 December 2024
Biotechnology
Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx. 19 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Shares of Swiss pharma giant Roche dipped 2.3% to 249.10 francs by midday after it reported disappointing results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s disease, treated for a minimum of 18 months while on stable symptomatic treatment. 19 December 2024
Pharmaceutical
US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR), also known as sciatica. 19 December 2024
Biotechnology
French biotech Igyxos Biotherapeutics today announced the appointments of Florent Ferré as chief executive and Dr Elke Bestel as chief medical officer to reinforce its management team and executive committee. 19 December 2024
Biotechnology
December 19, 2024
The US Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd), from Australia’s Mesoblast, whose shares rocketed 54% to A$3.05 on the news. 19 December 2024
All news
Pharmaceutical
San Diego, USA-based Neurocrine Biosciences today announced the launch of its Crenessity (crinecerfont) in the USA. 20 December 2024
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Biotechnology
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula (niraparib) and Jemperli (dostarlimab) in first line advanced ovarian cancer. 20 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting distinct domains of Factor XI, supporting its bid to bring new blood thinners to the market. 20 December 2024
Pharmaceutical
Denmark’s Zealand Pharma has been hit with a complete response letter (CRL) from the US regulator for glepaglutide, a long-acting GLP-2 analog. 20 December 2024
Biotechnology
Astellas Pharma has struck a licensing agreement with Sangamo Therapeutics to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. 20 December 2024
Biotechnology
Swiss pharma giant Novartis is to shut two sites belonging to its MorphoSys unit. 20 December 2024
Pharmaceutical
Denmark’s Novo Nordisk today announced headline results from REDEFINE 1, a Phase III trial in the global REDEFINE program, which it said were positive, but failed to impress investors, who pushed the firms shares down 19% to 601.30 kroner. 20 December 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). 20 December 2024
Pharmaceutical
US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL). 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) today recommending Pedmarqsi (anhydrous sodium thiosulfate), from British specialty pharma firm Norgine Pharmaceuticals, for the prevention of cisplatin-induced ototoxicity (CIO) in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors. 20 December 2024
Pharmaceutical
Shanghai-based Fangzhou, has entered into a strategic partnership with the Chinese business of Bristol Myers Squibb China, with the goal of enhancing digital platforms for chronic disease management. 19 December 2024
Biotechnology
Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx. 19 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Shares of Swiss pharma giant Roche dipped 2.3% to 249.10 francs by midday after it reported disappointing results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s disease, treated for a minimum of 18 months while on stable symptomatic treatment. 19 December 2024
Pharmaceutical
US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR), also known as sciatica. 19 December 2024
Biotechnology
French biotech Igyxos Biotherapeutics today announced the appointments of Florent Ferré as chief executive and Dr Elke Bestel as chief medical officer to reinforce its management team and executive committee. 19 December 2024
Biotechnology
December 19, 2024
The US Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd), from Australia’s Mesoblast, whose shares rocketed 54% to A$3.05 on the news. 19 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze